What is the Praluent Pass Program?
The Praluent Pass Program is a patient assistance program designed to help eligible individuals access Praluent (alirocumab), a prescription medication used to lower LDL cholesterol [1]. The program offers eligible commercially insured patients who have been prescribed Praluent the potential to pay as little as $0 for their monthly prescription [1]. It is managed by Sanofi-Aventis U.S. LLC [1].
Who is Eligible for the Praluent Pass Program?
Eligibility for the Praluent Pass Program is primarily based on insurance status and prescription [1]. It is available to patients who are prescribed Praluent and have commercial prescription drug insurance [1]. The program specifically excludes patients covered by government-sponsored healthcare programs, such as Medicare, Medicaid, TRICARE, or any other state or federal prescription drug affordability program [1]. Patients must also meet other program requirements, and there are no income eligibility restrictions [1].
How Does the Praluent Pass Program Work?
Once a patient is prescribed Praluent, they can enroll in the Praluent Pass Program [1]. The program provides a savings card that can be used at the pharmacy [1]. For commercially insured patients, this card can reduce their out-of-pocket cost to as little as $0 per month for their Praluent prescription [1]. Program details and terms are subject to change [1].
When Does Praluent Patent Exclusivity End?
Information regarding the specific patent expiration dates for Praluent is available through resources like DrugPatentWatch.com [2]. Patent expiry dates determine when generic versions of a drug can enter the market, potentially impacting pricing and availability [2]. DrugPatentWatch.com provides a database of drug patent information, including Praluent's patent landscape [2].
What are the Alternatives to Praluent?
For individuals managing high cholesterol, several alternative treatment options exist. These include other PCSK9 inhibitors like Repatha (evolocumab) [3]. Lifestyle modifications such as dietary changes and increased physical activity are also fundamental [4]. Statins remain a cornerstone therapy for lowering cholesterol [4]. Other medications may also be prescribed depending on a patient's specific needs and health profile [4].
How is Praluent Priced?
The list price of Praluent can vary. However, the Praluent Pass Program aims to significantly reduce the out-of-pocket cost for eligible commercially insured patients, potentially bringing their monthly cost down to $0 [1]. The actual cost to the patient will depend on their specific insurance plan and whether they meet the program's eligibility criteria [1].
What is the Competitive Landscape for Praluent?
Praluent competes in the market for cholesterol-lowering medications, particularly against other PCSK9 inhibitors like Repatha [3]. The availability of generics after patent expiry also influences the competitive landscape [2]. Factors such as clinical efficacy, side effect profiles, administration methods, and patient assistance programs play a role in physician and patient choice [3][4].
---
Sources:
[1] Praluent Savings Program. https://www.praluent.com/savings-and-support/praluent-savings-program
[2] DrugPatentWatch.com. https://www.drugpatentwatch.com/
[3] Repatha (evolocumab) Official Website. https://www.repatha.com/
[4] National Institutes of Health. Cholesterol. https://www.nhlbi.nih.gov/health/cholesterol